Company intelligence / Profile preview

Phantom Neuro

Austin, Texas, United Statesphantomneuro.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Phantom Neuro’s core platform, Phantom X, has demonstrated 94% accuracy in decoding real-time gestures across 11 essential hand and wrist movements in preclinical ASCENT studies. The company has received FDA Breakthrough Device and TAP designations. Human clinical trials are planned for 2025. No commercial products yet.

Therapeutic areas: OtherNeurology
Modalities: DeviceNeural interface technologyAI-powered prosthetic control system
Industry: Assistive Medical Devices

Partnerships

Ottobock (strategic investor, board seat, global leader in prosthetics/exoskeletons)

Beyond the preview

Go deeper on Phantom Neuro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phantom Neuro.

Explore the full profile